14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EVEX vs NUTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Nutex Health Inc. (NUTX) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas NUTX carries 51.7/100 (HOLD) at $167.10 (6.2x Forward P/E, 53.7% operating margin).
Growth vs. Quality Trade-Off: NUTX earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. EVEX 41.3/100 SELL) and 1.78β · 86% Vol risk profile, whereas EVEX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile NUTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVEX vs NUTX. Trailing 12-month operating profitability (EVEX 0.0% vs NUTX 53.7%) and valuation multiples (EVEX N/M vs NUTX 6.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Aerospace & Defense value chain with $597.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NUTX Moat ProfileHigh-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.2B market capitalization and 53.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EVEX vs NUTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Nutex Health Inc. (NUTX) is the stronger overall head-to-head candidate over Eve Holding, Inc. (EVEX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EVEX carries a Unified Composite Score of 41.3/100 (SELL) at $1.70 (N/M Forward P/E, 0.0% operating margin), whereas NUTX carries 51.7/100 (HOLD) at $167.10 (6.2x Forward P/E, 53.7% operating margin). Growth vs. Quality Trade-Off: NUTX earns the overall head-to-head edge with a stronger Unified Composite Score (51.7/100 HOLD vs. EVEX 41.3/100 SELL) and 1.78β · 86% Vol risk profile, whereas EVEX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: EVEX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.8); meanwhile NUTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EVEX leads the Growth & Scale pillar: EVEX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NUTX at -18.7% YoY revenue growth and -26.4% YoY earnings growth on $797M TTM revenue (51.3% gross margin, 53.7% operating margin). On trailing 12-month operating scale, EVEX generates N/A in USD-normalized revenue versus $797M for NUTX. In operating R&D and SG&A reinvestment, EVEX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUTX.
NUTX screens cheaper on headline valuation multiples. EVEX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NUTX trades at 6.2x Forward P/E, 7.5x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (34.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVEX (-300.9% ROE) versus NUTX (47.6% ROE) capital efficiency.
In options market volatility and institutional positioning, EVEX carries 72.3% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.71β · 96% Vol realized risk). By comparison, NUTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.78β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.